DocWire News Editors

DocwireNews

Researchers have recently created a<a href="https://www.docwirenews.com/abstracts/scoring-of-coronary-artery-disease-characteristics-on-coronary-ct-angiograms-by-using-machine-learning/"> machine learning</a> computer model that can simulate the metabolism of cancer cells. This team, from the Life Sciences Research Unit at the University of Luxembourg, used this technique to analyze the effects of various drugs on stopping cancer development. Their findings were covered in an open access article in the Lancet journal <a href="https://www.ebiomedicine.com/article/S2352-3964(19)30285-3/fulltext">EBioMedicine</a>.Once cells undergo morphological changes to become malignant, they begin utilizing different metabolic processes than healthy cells. Though this metabolic pathway is focused acutely on growth and proliferation, this limitation makes the cancer cell less able to adapt to changes.&ldquo;Their metabolism is much leaner than that of healthy cells, as they are just focused on growth,&rdquo; explained Thomas Sauter, Professor of Systems Biology at the University of Luxembourg and lead author of the paper. &ldquo;However, this makes them more vulnerable to interruptions in the chain of chemical reactions that the cells depend on. Whereas healthy cells can take alternative routes when one metabolic path is disabled, this is more difficult for cancer cells. In our study, we investigated how drugs or combinations of drugs could be used to switch off certain proteins in cancer cells and thereby interrupt the cell&rsquo;s metabolism.&rdquo;After creating digital models of both healthy and cancerous cells, the researchers then incorporated genetic data from 10,000 patients within the Cancer Genome Atlas of the American National Cancer Institute. These computer models were used by the researchers to simulate the effects of different compounds on cellular metabolism. Simulating with the cancer cell models showed which drugs can effectively inhibit cancer growth, while simulating with the healthy cells tested the safety of these drugs. By screening for drugs that are effective and safe, this system allows researchers to rule out poor candidates before lab testing.The researchers assessed roughly 800 drugs on these cell models using their predictive machine learning model and 40 of these tested compounds were found to combat cancer development. About half of these drugs were already identified as <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/radiation-therapy-as-a-bridging-strategy-for-car-t-cell-therapy-with-axicabtagene-ciloleucel-in-diffuse-large-b-cell-lymphoma/">anti-cancer therapies</a>, but only 17 are currently approved only for other treatments.&ldquo;Our tool can help with the so-called &lsquo;drug repositioning&rsquo;, which means that new therapeutically purposes are found for existing medication,&rdquo; Sauter said. &ldquo;This could significantly reduce the cost and time for drug development.&rdquo;The models tested so far have only been for colorectal cancer, but Sauter claims that the <a href="https://www.docwirenews.com/docwire-pick/future-of-medicine-picks/how-idx-is-paving-the-way-for-artificial-intelligence-use-in-medicine/">AI system</a> would work for all types of cancer as well. He and his colleagues will potentially move into developing commercial uses for this technique.First author Dr. Maria Pacheco highlighted the efficiency of their mathematical approach. &ldquo;We managed to create 10,000 patient models within one week, without the use of high-performance computing. This is exceptionally fast,&rdquo; explained Pacheco, who is also a postdoctoral researcher at the University of Luxembourg.Another collaborator on the study, Dr. Elisabeth Letellier, feels that their work could revolutionize how individualized cancer therapy regimens are designed. &ldquo;In the future, this could allow us to build models of individual cancer patients and virtually test drugs in order to find the most efficient combination. This could also bring fresh hope to patients for whom known therapies haven proven to be ineffective,&rdquo; said Letellier, principal investigator at the Molecular Disease Mechanisms group at the University of Luxembourg.<blockquote class="twitter-tweet">
? <a href="https://twitter.com/hashtag/uni_lu?src=hash&amp;ref_src=twsrc%5Etfw">#uni_lu</a> researchers have developed a computer model that simulates the metabolism of <a href="https://twitter.com/hashtag/cancer?src=hash&amp;ref_src=twsrc%5Etfw">#cancer</a> cells. 
&#8505;&#65039; They used the programme to investigate how combinations of drugs could be used more effectively to stop <a href="https://twitter.com/hashtag/tumour?src=hash&amp;ref_src=twsrc%5Etfw">#tumour</a> growth. <a href="https://twitter.com/hashtag/research?src=hash&amp;ref_src=twsrc%5Etfw">#research</a> <a href="https://t.co/SuIWTz7bPU">https://t.co/SuIWTz7bPU</a>
&mdash; uni.lu (@uni_lu) <a href="https://twitter.com/uni_lu/status/1146067597995081728?ref_src=twsrc%5Etfw">July 2, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Computer Model Uses Machine Learning to Support Cancer Therapy

Researchers have recently created a machine learning computer model that can simulate the metabolism of cancer cells. This team, from the Life Sciences Research Unit at the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe